In this prospective cohort study, the prognostic and predictive value of baseline and post-treatment levels of serum VEGF-A, VEGF-B, sPD-1, and sPD-L1 were investigated in 55 advanced NSCLC patients treated with immune checkpoint inhibitors (ICIs). The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.